Consistently, the motor nerve conduction study confirmed the absence of demyelinated processes in the tail caudal nerves after spinal cord injury (the CMAP showed normal biphasic potentials, similar amplitudes, and similar conduction velocities in all of the rats) (Table 4)
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
If you are experiencing a medical emergency, call 911 right away.
And absent more rigorous studies, the team warned, it will remain difficult to convince the broader medical community that this so-called wonderful compound meets the criteria of a legitimate therapeutic agent. But it turns out, one group had begun to give it a go anyway